top of page
Lars+Terenius_30.jpg

Prof. Dr. Lars Y. Terenius

(European) Chairman of CDA Scientific Advisory Board

Positions and Employment

​

1969-1976       Senior Scientist, Department of Pharmacology, University of Uppsala

1976-1977       Associate Research Professor, Swedish Medical Research Council

1977-1988       Professor and Chairman, Department of Pharmacology, Faculty of Pharmacy, University of Uppsala

1988                Professor, Experimental Alcohol and Drug Addiction Research, Karolinska Institute, Stockholm

1988-1989       Fogarty Scholar-in-Residence, National Institutes of Health, Washington, D.C.

1991                Visiting Professor, Rockefeller University, New York, NY

1998                Vallee Visiting Professor, Harvard University, Boston, MA

1992 & 1993    Visiting scientist, Scripps Research Institute, La Jolla, CA

1995, 96, 97    Visiting scientist The Neurosciences Institute, San Diego, CA

2002                R.B. Woodward Visiting Professor, Harvard University, Boston, MA

2004-2011       Adjunct Full Professor, The Scripps Research Institute, La Jolla, CA

2011-present   Visiting Professor, The Department of Cellular and Molecular Neuroscience, The Scripps Research
                        Institute, La Jolla, CA

​

Other Experience and Professional Memberships

​

1979-1981     Member of Expert Committee "Future Directions of Research", Swedish Ministry of Education

1982-1986     Member of the Board of Research and Education within Health Professions, Swedish Ministry of Education

1988-1995     Member of the Board of the Swedish Medical Research Council

1992-1997     Head of Karolinska Center for PET (positron emission tomography) Studies

1994-2008     Director, Center for Molecular Medicine (CMM) Karolinska University Hospital

1996 -2005    Chairman, Committee on Research Integrity and Policy, Karolinska Institutet

2000-2010     Director, Wallenberg Consortium North for Functional Genomics

2011-2012     Medical Expert on Investigation on Scientific Integrity, Copenhagen University, Denmark

 

Memberships

​

1985             Royal Society of Sciences (Uppsala)

1987             Royal Academy of Sciences (Stockholm)

1989             Academia Europaea (Cambridge)

1990             Nobel Assembly on Physiology or Medicine

1999             American Academy of Arts and Sciences (Boston, MA)

 

Prizes

​

1976            Hilda and Alfred Erikssons Prize (Stockholm)

1977            Pacesetter Award (Washington, D.C.)

1978            Gairdner Award (Toronto)

1980            Jahre Award (Oslo)

1984            Björkéns Prize (Uppsala)

1999            Olof Rudbeck Prize (Uppsala)

2000            Ipsen Award (Paris)

 

Honorary degrees

​

1981            Uppsala University

1983            University of Trondheim, Norway

2005            University of Sofia, Bulgaria

Lars Terenius, selected publications from a total of 605 original articles

 

  1. Oasa S, Vukojevic V, Rigler R, Tsigelny IF, Changeux JP, Terenius L. A strategy for designing allosteric modulators of transcription factor dimerization. Proc Natl Acad Sci U S A. 2020;117(5):2683-6.

  2. Nassan M, Veldic M, Winham S, Frye MA, Larrabee B, Colby C, et al. Methylation of Brain Derived Neurotrophic Factor (BDNF) Val66Met CpG site is associated with early onset bipolar disorder. J Affect Disord. 2020;267:96-102.

  3. Tobin SJ, Wakefield DL, Terenius L, Vukojevic V, Jovanovic-Talisman T. Ethanol and Naltrexone Have Distinct Effects on the Lateral Nano-organization of Mu and Kappa Opioid Receptors in the Plasma Membrane. ACS Chem Neurosci. 2019;10(1):667-76.

  4. Tiiman A, Jelic V, Jarvet J, Jaremo P, Bogdanovic N, Rigler R, et al. Amyloidogenic Nanoplaques in Blood Serum of Patients with Alzheimer's Disease Revealed by Time-Resolved Thioflavin T Fluorescence Intensity Fluctuation Analysis. J Alzheimers Dis. 2019;68(2):571-82.

  5. Papadopoulos DK, Skouloudaki K, Engstrom Y, Terenius L, Rigler R, Zechner C, et al. Control of Hox transcription factor concentration and cell-to-cell variability by an auto-regulatory switch. Development. 2019;146(12).

  6. Krmpot AJ, Nikolic SN, Oasa S, Papadopoulos DK, Vitali M, Oura M, et al. Functional Fluorescence Microscopy Imaging: Quantitative Scanning-Free Confocal Fluorescence Microscopy for the Characterization of Fast Dynamic Processes in Live Cells. Anal Chem. 2019;91(17):11129-37.

  7. Hertz E, Terenius L, Vukojevic V, Svenningsson P. GPR37 and GPR37L1 differently interact with dopamine 2 receptors in live cells. Neuropharmacology. 2019;152:51-7.

  8. Bonito-Oliva A, Schedin-Weiss S, Younesi SS, Tiiman A, Adura C, Paknejad N, et al. Conformation-specific antibodies against multiple amyloid protofibril species from a single amyloid immunogen. J Cell Mol Med. 2019;23(3):2103-14.

  9.  Rogacki MK, Golfetto O, Tobin SJ, Li T, Biswas S, Jorand R, et al. Dynamic lateral organization of opioid receptors (kappa, muwt and muN40D ) in the plasma membrane at the nanoscale level. Traffic. 2018.

  10. Matzeu A, Terenius L, Martin-Fardon R. Exploring Sex Differences in the Attenuation of Ethanol Drinking by Naltrexone in Dependent Rats During Early and Protracted Abstinence. Alcohol Clin Exp Res. 2018;42(12):2466-78.

  11. D'Addario C, Shchetynsky K, Pucci M, Cifani C, Gunnar A, Vukojevic V, et al. Genetic variation and epigenetic modification of the prodynorphin gene in peripheral blood cells in alcoholism. Prog Neuropsychopharmacol Biol Psychiatry. 2017;76:195-203.

  12. Cupic Z, Stanojevic A, Markovic VM, Kolar-Anic L, Terenius L, Vukojevic V. The HPA axis and ethanol: a synthesis of mathematical modelling and experimental observations. Addict Biol. 2017;22(6):1486-500.

  13. Adem A, Madjid N, Kahl U, Holst S, Sadek B, Sandin J, et al. Nociceptin and the NOP receptor in aversive learning in mice. Eur Neuropsychopharmacol. 2017;27(12):1298-307.

  14. Comasco E, Vumma R, Toffoletto S, Johansson J, Flyckt L, Lewander T, et al. Genetic and Functional Study of L-Type Amino Acid Transporter 1 in Schizophrenia. Neuropsychobiology. 2016;74(2):96-103.

  15. Andreou D, Soderman E, Axelsson T, Sedvall GC, Terenius L, Agartz I, et al. Associations between a locus downstream DRD1 gene and cerebrospinal fluid dopamine metabolite concentrations in psychosis. Neurosci Lett. 2016;619:126-30.

  16. Papadopoulos DK, Krmpot AJ, Nikolic SN, Krautz R, Terenius L, Tomancak P, et al. Probing the kinetic landscape of Hox transcription factor-DNA binding in live cells by massively parallel Fluorescence Correlation Spectroscopy. Mech Dev. 2015;138 Pt 2:218-25.

  17. Andreou D, Soderman E, Axelsson T, Sedvall GC, Terenius L, Agartz I, et al. Cerebrospinal fluid monoamine metabolite concentrations as intermediate phenotypes between glutamate-related genes and psychosis. Psychiatry Res. 2015;229(1-2):497-504.

  18. Tobin SJ, Cacao EE, Hong DW, Terenius L, Vukojevic V, Jovanovic-Talisman T. Nanoscale effects of ethanol and naltrexone on protein organization in the plasma membrane studied by photoactivated localization microscopy (PALM). PLoS One. 2014;9(2):e87225.

  19. Steinberg S, de Jong S, Mattheisen M, Costas J, Demontis D, Jamain S, et al. Common variant at 16p11.2 conferring risk of psychosis. Mol Psychiatry. 2014;19(1):108-14.

  20. Lundius EG, Vukojevic V, Hertz E, Stroth N, Cederlund A, Hiraiwa M, et al. GPR37 protein trafficking to the plasma membrane regulated by prosaposin and GM1 gangliosides promotes cell viability. J Biol Chem. 2014;289(8):4660-73.

  21. Carlred L, Gunnarsson A, Sole-Domenech S, Johansson B, Vukojevic V, Terenius L, et al. Simultaneous imaging of amyloid-beta and lipids in brain tissue using antibody-coupled liposomes and time-of-flight secondary ion mass spectrometry. J Am Chem Soc. 2014;136(28):9973-81.

  22. Andreou D, Soderman E, Axelsson T, Sedvall GC, Terenius L, Agartz I, et al. Polymorphisms in genes implicated in dopamine, serotonin and noradrenalin metabolism suggest association with cerebrospinal fluid monoamine metabolite concentrations in psychosis. Behav Brain Funct. 2014;10:26.

  23. Sole-Domenech S, Sjovall P, Vukojevic V, Fernando R, Codita A, Salve S, et al. Localization of cholesterol, amyloid and glia in Alzheimer's disease transgenic mouse brain tissue using time-of-flight secondary ion mass spectrometry (ToF-SIMS) and immunofluorescence imaging. Acta Neuropathol. 2013;125(1):145-57.

  24. Lundius EG, Stroth N, Vukojevic V, Terenius L, Svenningsson P. Functional GPR37 trafficking protects against toxicity induced by 6-OHDA, MPP+ or rotenone in a catecholaminergic cell line. J Neurochem. 2013;124(3):410-7.

  25. Saetre P, Grove J, Borglum AD, Mors O, Werge T, Andreassen OA, et al. Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and age at onset of schizophrenia: no consistent evidence for an association in the Nordic population. Am J Med Genet B Neuropsychiatr Genet. 2012;159B(8):981-6.

  26. Lindholm Carlstrom E, Saetre P, Rosengren A, Thygesen JH, Djurovic S, Melle I, et al. Association between a genetic variant in the serotonin transporter gene (SLC6A4) and suicidal behavior in patients with schizophrenia. Behav Brain Funct. 2012;8:24.

  27. Jonsson EG, Saetre P, Nyholm H, Djurovic S, Melle I, Andreassen OA, et al. Lack of association between the regulator of G-protein signaling 4 (RGS4) rs951436 polymorphism and schizophrenia. Psychiatr Genet. 2012;22(5):263-4.

  28. Holtze M, Saetre P, Engberg G, Schwieler L, Werge T, Andreassen OA, et al. Kynurenine 3-monooxygenase polymorphisms: relevance for kynurenic acid synthesis in patients with schizophrenia and healthy controls. J Psychiatry Neurosci. 2012;37(1):53-7.

bottom of page